english.prescrire.org > Spotlight > 100 most recent > Prescrire's ratings of new drugs in 2022

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Prescrire's ratings of new drugs in 2022

  Marketing Authorisations  Only 11 of the 124 new marketing authorisations analysed and rated in our French edition in 2022 represented a notable therapeutic advance for patients.

Prescrire’s ratings of new products and indications over the past 10 years
 
 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
Bravo  BRAVO
0 1 0 0 0 0 0 1 0 0
A Real Advance  A REAL ADVANCE
0 2 3 1 1 2
 1 2 3 0
Offers an advantage  OFFERS AN ADVANTAGE
6 5 5 5 9 11 10 6 14 11
Possibly helpful  POSSIBLY HELPFUL 
12 15 15 9 18 22 13 18 19 23
Nothing new  NOTHING NEW
48 35 43 56 45 50 61 55 51 63
Judgement reserved  JUDGEMENT RESERVED
9 10 6 5 4 5
 9 17 12 13
Not acceptable  NOT ACCEPTABLE 
15 19 15 16 15 9
 14 10 9 14
TOTAL 90 87 87 92 92 99 108 109 108 124
 
Therapeutic advances in 2022 compared with
the previous 9 years
Therapeutic advances 2012-2021
 

In summary: a disappointing year

2022 was a return to the bad old days for medicines in Europe. Therapeutic advances were few and far between. Most newly authorised products or indications offered no proven advantages over existing treatment options, or were excessively dangerous. And yet again, certain pharmaceutical companies gave too little consideration to the ease of use of their products, choosing to market them in pack sizes ill-suited to the doses to be administered.


©Prescrire 1 April 2023

Source: "Prescrire's ratings of new drugs in 2022: a brief review" Prescrire International 2023; 32 (247): 99-101. Free.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


For more information:

"Prescrire's ratings for new drugs
and new indications"
(March 2023)
Free


See also:

"The Prescrire Drug Awards
for 2022” 
(March 2023)
Free


Read more:

All the subjects in
Prescrire's Spotlight
Free >